The place of immunotherapy in the management of HCV-induced vasculitis: an update - Wikidata - awgldk - TriplyDB

The place of immunotherapy in the management of HCV-induced vasculitis: an update

The place of immunotherapy in the management of HCV-induced vasculitis: an update

http://www.wikidata.org/entity/Q27015124

about

Diagnosis and therapeutic options for peripheral vasculitic neuropathy.Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.

P2860

Q38398833-4A8483C1-272E-4C7C-838E-550384FB05D9 Q41654330-D05544AC-D5A1-4F02-A6DF-E43D473F6290

P2860

The place of immunotherapy in the management of HCV-induced vasculitis: an update

http://www.wikidata.org/entity/Q27015124

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@ast

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@en

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@nl

type

label

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@ast

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@en

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@nl

prefLabel

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@ast

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@en

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@nl

P1433

Q27015124-8F879166-542C-4392-9D15-0666CA4A2493

P1476

Q27015124-2055A594-4C31-4F61-859A-DCF5BD806FAD

P2093

Q27015124-2E4A6A21-05AB-475A-9D52-F1E2A4FBB1B4

Q27015124-79C6F184-C20E-49CD-A4FC-B5A079368439

Q27015124-8E201281-941F-4EB1-AC00-C350F4B9CFC8

P275

Q27015124-7EC9E426-C65E-45F5-A266-7F483F21D524

P2860

Q27015124-0BF76DAD-1CDF-42F7-B479-5E2EE43C3A62

Q27015124-103B62FA-71CA-4B16-B3DD-B1C30CA23F0D

Q27015124-162629FB-F5C0-4764-863E-3167D2BE25C0

Q27015124-18B5CBC5-E586-477D-878A-BB451D176DF0

Q27015124-1A8D60C5-F395-43EF-8760-0C0A19A8F868

Q27015124-22009151-B855-4152-92D6-CAAD94951AF1

Q27015124-239BF04E-34AB-4E4C-ADA0-BB5997073BB8

Q27015124-27326DDD-3313-4216-9045-FF4C97B39375

Q27015124-284013B7-5DE9-43F3-A00C-1E512FC42489

Q27015124-2F573470-48DA-4F64-A3E6-FE333F6A327F

P304

Q27015124-6279BC0F-0D6D-4E77-9500-0F61869DEB02

P31

Q27015124-5F87FB57-F274-4561-9E42-6CDAA4F6BA89

Q27015124-FA3779D7-2B76-4BAA-8A8A-F4A5DFC797ED

P356

Q27015124-2387BA6F-5D2B-461B-AD25-C4EBA318AB4E

P407

Q27015124-C2FDCE14-869A-45F6-83E2-75BA868974FF

P478

Q27015124-C0ACA4CE-C5FC-42C6-B385-CAC1E24D8EA3

P50

Q27015124-E97822D5-9CD4-47AC-B72A-18E26F04EBAD

P5008

Q27015124-F6CEF608-D203-49F0-88CC-4E1ECE9B0363

P577

Q27015124-A3CA1D87-B283-429C-A26B-AF0CCC8A4F4A

P5875

Q27015124-CF209CF0-114C-4D68-BE72-7689C5AD3BE7

P698

Q27015124-B229F0B9-2211-413C-ACE6-32424A31DAD5

P921

Q27015124-1049DCD2-56BD-4F67-812F-9C3D984C2E53

Q27015124-8200D4B0-1E0B-40E3-B11C-894593CDF4A3

Q27015124-A484A1A5-DC86-4363-A01D-84946C8B5735

Q27015124-C73DB72F-A50B-4FA8-96E5-4A26FA028777

Q27015124-ECE609E4-90BD-4DA9-ACA4-8522EC6F343E

P932

Q27015124-3DE07B8C-B2B7-47B1-9BC9-B86C6A2205DF

P356

P1433

Clinical and Developmental Immunology

P1476

The place of immunotherapy in the management of HCV-induced vasculitis: an update

@en

P2093

Gilles Kaplanski

http://www.w3.org/2001/XMLSchema#string

Laurent Chiche

http://www.w3.org/2001/XMLSchema#string

Noemie Jourde

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Occult hepatitis C: how convincing are the current data?

Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.

Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits.

P304

315167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/315167

http://www.w3.org/2001/XMLSchema#string

P407

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Stanislas Bataille

P5008

P577

2012-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230750150

http://www.w3.org/2001/XMLSchema#string

P698

22927871

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

P932

3426208

http://www.w3.org/2001/XMLSchema#string